Drug Profile


Alternative Names: 869682; GSK 869682; GW869682X; KGT-1251

Latest Information Update: 06 Jun 2008

Price : $50

At a glance

  • Originator Kissei Pharmaceutical
  • Developer GlaxoSmithKline
  • Class Antihyperglycaemics; Glucosides
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 06 Jun 2008 Kissei and GlaxoSmithKline extended their agreement for SGLT2 inhibitors in Japan, South Korea, China and Taiwan
  • 29 Feb 2008 Discontinued - Phase-II for Type-2 diabetes mellitus in USA (PO)
  • 29 Feb 2008 Discontinued - Phase-II for Obesity in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top